Three years after IMT recurrence, disease remains under control.<h4>Conclusion</h4>This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. Here, SQSTM1 is linked to inflammatory myofibroblastic tumor.